MK-2870 is an investigational medication being studied for its effectiveness in treating advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with specific genetic changes, such as EGFR mutations. The trial aims to see how well this medication works compared to standard chemotherapy treatments.

Docetaxel is a type of chemotherapy used in this study as a comparison to MK-2870. It works by interfering with the growth of cancer cells, slowing or stopping their spread in the body.

Pemetrexed is another chemotherapy option used in the trial. It helps to block the growth of cancer cells by interfering with their ability to use folic acid, which is necessary for their growth and survival.

Non-small Cell Lung Cancer (NSCLC) – This is the most common type of lung cancer, accounting for about 85% of all cases. It typically starts in the epithelial cells lining the lungs and can grow and spread to other parts of the body. NSCLC is often categorized into subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, based on the type of cells affected. The disease progresses through stages, from localized tumors to more advanced stages where cancer has spread to lymph nodes or other organs. Symptoms may include a persistent cough, chest pain, and difficulty breathing, but they often appear only after the disease has advanced. The progression and symptoms can vary significantly depending on the specific genetic mutations present, such as those affecting the epidermal growth factor receptor (EGFR).